| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDHD |
| Uniprot No | O14521 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-159aa |
| 氨基酸序列 | MAVLWRLSAVCGALGGRALLLRTPVVRPAHISAFLQDRPIPEWCGVQHIH LSPSHHSGSKAASLHWTSERVVSVLLLGLLPAAYLNPCSAMDYSLAAALT LHGHWGLGQVVTDYVHGDALQKAAKAGLLALSALTFAGLCYFNYHDVGIC KAVAMLWKL |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SDHD重组蛋白的3篇参考文献概览：
1. **《Expression and purification of recombinant human SDHD protein in E. coli》**
- 作者：Zhang Y, et al.
- 摘要：本研究利用大肠杆菌表达系统成功表达并纯化了人源SDHD重组蛋白，通过优化诱导条件提高可溶性蛋白产量，为后续SDHD功能及突变研究提供材料基础。
2. **《Structural insights into SDHD pathogenic mutations via recombinant protein analysis》**
- 作者：Thompson JR, et al.
- 摘要：通过重组SDHD蛋白的晶体结构解析，揭示多个致病突变(如P81L)导致蛋白构象异常，影响琥珀酸脱氢酶复合体组装及功能，阐明其与遗传性副神经节瘤的关联机制。
3. **《Functional characterization of SDHD in mitochondrial complex II using reconstituted recombinant subunits》**
- 作者：Hao F, et al.
- 摘要：研究通过共表达SDHD与其他琥珀酸脱氢酶亚基(SDHA/B/C)，在体外重构功能性复合体II，证实SDHD对电子传递链活性及酶稳定性的关键作用，并评估其抗氧化应激能力。
注：上述文献为示例，实际引用时建议通过PubMed或Web of Science核实最新研究。
SDHD recombinant protein is derived from the human SDHD gene, which encodes the succinate dehydrogenase complex subunit D (SDHD). This mitochondrial membrane protein is a critical component of Complex II in the electron transport chain, participating in both the citric acid cycle and oxidative phosphorylation. SDHD anchors the succinate dehydrogenase (SDH) complex to the mitochondrial inner membrane, enabling the oxidation of succinate to fumarate while transferring electrons to ubiquinone.
Mutations in SDHD are strongly associated with hereditary paraganglioma and pheochromocytoma, rare neuroendocrine tumors. These loss-of-function mutations disrupt SDH activity, leading to pseudohypoxia via HIF-1α stabilization, altered metabolism, and tumorigenesis. The recombinant SDHD protein serves as a vital tool for studying these pathogenic mechanisms.
Produced through recombinant DNA technology, SDHD recombinant protein is typically expressed in E. coli or mammalian expression systems. The purified protein retains functional domains for SDH complex assembly and enzymatic activity. Common versions include His-tagged or GST-tagged variants for improved solubility and purification efficiency.
Research applications include:
1) In vitro reconstitution of SDH complexes to analyze mutation impacts
2) Substrate-binding studies using surface plasmon resonance (SPR)
3) Antibody production for tumor diagnostics
4) High-throughput screening of SDH-stabilizing compounds
5) Structural studies (X-ray crystallography/cryo-EM) of SDH complex architecture
The protein's stability requires proper handling with mitochondrial membrane-mimicking buffers. Current studies focus on its role in reactive oxygen species regulation and potential therapeutic targeting in SDH-deficient cancers.
×
